Three Mutations Convert the Selectivity of a Protein Sensor From Nicotinic Agonists to S-Methadone For Use in Cells, Organelles, and Biofluids

Anand K. Muthusamy^{1,2}, Charlene H. Kim¹, Scott C. Virgil², Hailey J. Knox², Jonathan S. Marvin³, Aaron L. Nichols¹, Bruce N. Cohen¹, Dennis A. Dougherty², Loren L. Looger⁴, and Henry A. Lester^{*1}

¹Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91106

²Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91106

³Howard Hughes Medical Institute, Janelia Research Campus, Ashburn, VA 20147

⁴Howard Hughes Medical Institute, University of California, San Diego, San Diego, California, 92093

*Corresponding author

Abstract: We report a reagentless, intensity-based S-methadone fluorescent sensor, iS-methadoneSnFR, consisting of a circularly permuted GFP inserted within the sequence of a mutated bacterial periplasmic binding protein (PBP). We used directed evolution to convert a previously reported nicotine-binding PBP to a selective S-methadone-binding sensor, via three mutations in the PBP's second shell and hinge regions. iS-methadoneSnFR displays sensitivity across the pharmacologically relevant range and selectivity against endogenous analytes and other opioids. Robust iS-methadoneSnFR responses in human sweat and saliva and mouse serum enable diagnostic uses. Genetic encoding and imaging in mammalian demonstrated the acid trapping of S-methadone in the Golgi apparatus where opioid receptors can signal. This work shows a straightforward strategy in adapting existing PBPs to serve real-time applications ranging from subcellular to personal pharmacokinetics.

Main text:

We report the first selective real-time fluorescent biosensor for a small molecule opioid, “intensity-based S-methadone sensing fluorescent reporter” or “iS-methadoneSnFR” (**Figure 1**). To employ the indicator for quantitative dynamic opioid measurements in cells and biofluids, we engineered iS-methadoneSnFR to meet necessary criteria: (1) sensitivity in the pharmacological range, (2) selectivity against endogenous molecules, (3) selectivity against exogenous drugs, including those of the same drug class, (4) photostability for the duration of measurements, (5) physical stability outside cells, and (6) reversible binding with ~second resolution.

The risk of opioid-use disorder and death by overdose has increased alongside the worldwide access to highly potent opioid agonists¹. Nevertheless, opioids remain essential analgesics. Since the 1960s, methadone maintenance therapy (MMT) has served to reduce harm from opioid addiction^{2,3}. MMT relies on pharmacokinetics: oral methadone's onset is slower than that of injected or inhaled μ -opioids, and its effects last much longer due to a ~24 h half-life⁴. Therefore, despite acting as a μ -opioid agonist, methadone staves off withdrawal symptoms without producing the euphoria associated with other agonists⁴. However, interindividual variability in the metabolism of methadone, partiality due to polymorphisms in cytochrome P450 isotypes^{5,6}, can lead to therapeutic failures⁷. Methadone is clinically administered as the racemate and measuring either enantiomer is suitable for therapeutic drug monitoring⁸. Drug metabolism is conventionally addressed by blood draw, but this method is laborious, invasive, and restricted to the clinic. An optimal methadone readout would enable personalized dosing regimens, by producing real-time tracking of [methadone] in biological fluids and facilitating tapering from potent opioids. Within a subject, opioid pharmacokinetics also varies at the level of intracellular compartments to produce acid trapping and diverse interactions with receptors including chaperoning and activation^{9,10,11}. In both cases, a sensor with *in situ* readout and ~second resolution is required.

Figure 1: (a) Crystal structure of iNicSnFR3a (PDB: 7S7T) mutated *in silico* to iS-methadoneSnFR (mutations shown in orange spheres). All but one putative cation- π residue in iNicSnFR3a were maintained in iS-methadoneSnFR's binding pocket (critical residues Y65, Y357, and Y460 shown as yellow spheres). (b) Biosensor mechanism: in the unbound state, GFP's chromophore has a poor environment for fluorescence. The PBP binds S-methadone with a “Venus flytrap” conformational change, increasing the brightness of the GFP chromophore.

Figure 2: (a) Directed evolution strategy. (b) Fluorescence responses to S-methadone. iNicSnFR3a (black) has several variants (faded curves), of which one has markedly better sensitivity, owing to the N11E mutation (blue). This lead was evolved to the final iS-methadoneSnFR (red), which included re-optimization at position 11. Only the final biosensor had sufficient sensitivity at 1 μM (vertical black line; the relevant maintenance concentration). (c) Shift in selectivity from iNicSnFR3a (black) to iS-methadoneSnFR (red) measured by S-slope (see text). Note the scale change at the axis break.

In a pioneering *de novo* protein design campaign for an opioid sensor, binding of fentanyl produced a conformational switch in a transcription factor¹² but required a cellular readout and hours-to-days temporal resolution. We hypothesized that all criteria could be satisfied by a single-chain sensor comprising a mutated bacterial periplasmic binding protein (PBP), a variant of the choline-binding protein OpuBC from *Thermoanaerobacter sp513*, interrupted by a circularly permuted GFP (cpGFP)(**Figure 1**)^{13,14,15}. The cpGFP insertion approach has also been used in Ca^{2+} sensors (the GCaMP series) and in neurotransmitter sensors^{13,16}. Our strategy consisted of (1) screening each methadone enantiomer against a previously reported nicotine biosensor, iNicSnFR3a, and its variants¹⁴ and (2) iterative site-saturation mutagenesis to select for S-methadone and against cholinergic ligands (**Figure 2a**). We performed chiral resolution on racemic methadone to isolate (+)-S-methadone and (-)-R-methadone (assigned by optical rotation¹⁷) with analytical purity and 99% enantiomeric excess (**Figure S1**). While there is no structural homology or pharmacological overlap between nicotinic and μ -opioid receptors, several variants of nicotinic drug biosensors displayed weak fluorescence

responses to S-methadone (**Figure 2b**). Although the PBP had no enantioselective pressure for binding its achiral ligand choline, all variants screened to date displayed enantioselectivity for S-methadone (**Figure S2**). Dose-response relations were fit to the Hill equation to determine an EC_{50} and $\Delta F_{\text{max}}/F_0$. In the linear portion of the dose-response relation we define the increase in fluorescence per micromolar, “S-slope”, as a metric of biosensor sensitivity: $(\Delta(F/F_0)/(\Delta[\text{ligand}]))$ at $[\text{drug}] \ll \text{EC}_{50}^{18}$. For a Hill coefficient of ~ 1.0 , the S-slope equals the ratio $(\Delta F_{\text{max}}/F_0)/\text{EC}_{50}$. A variant of iNicSnFR3a, iNicSnFR3b, provided the largest dynamic range for both S-methadone and R-methadone (**Figure S2**) and served as the input to several rounds of directed evolution.

We selected for both an increase in sensitivity to S-methadone and a decrease in sensitivity to nicotinic ligands. We chose mutation sites based on a crystal structure of iNicSnFR1 (PDB: 6EFR) and directed evolution of iNicSnFR3a¹⁴. The resulting sensor displayed a ~ 16 -fold improvement in sensitivity over iNicSnFR3a; $\Delta F/F_0$ increased to 3.76 ± 0.16 at $1 \mu\text{M}$, the representative plasma maintenance concentration⁸ (**Figure 2b**). Notably, iS-methadoneSnFR displayed sensitivity to S-methadone that exceeded the sensitivity for any of the original cholinergic ligands and displayed a marked shift in ligand selectivity (**Figure 2c**). iS-methadoneSnFR displayed near-zero response for physiologically or pharmacologically relevant steady-state acetylcholine (ACh), choline, varenicline, and nicotine concentrations ($\sim 1 \mu\text{M}$, 10 to $20 \mu\text{M}^{19}$, 0 to 100 nM^{20} and ~ 25 to $\sim 500 \text{ nM}$, respectively²¹ (**Figure 4a below**)).

We characterized iS-methadoneSnFR's binding using docking and biochemical studies. Although only three mutations were required to generate iS-methadoneSnFR from iNicSnFR3a/3b, advantageous mutations were rare: $\sim 1\%$ of all mutations screened were accepted as improvements. Docking S-methadone into recently reported structures of liganded iNicSnFR3a²² showed that the N-methyl groups of S-methadone lie 4.6 and $5.5 \text{ \AA}$ from the aromatic groups of Y357 and Y65, respectively (slightly greater than the distance from the beta carbons of varenicline to these two groups). In the initial round of mutations, most sites yielded no improvement, except for a W436F mutation spatially near Y65 and Y357 (**Figure S3**). We previously reported nicotine and varenicline making cation- π interactions with Y65 and Y357 in iNicSnFR3a (PDB: 7S7T, 7S7U, respectively)²². Each nicotinic ligand bears a protonated nitrogen lying midway on the axis of the aromatic centroids of Y65 and Y357 (**Figure 3a**). In the subsequent round, second-shell mutation N11V created additional volume next to F12, in the second shell. Finally, the third round yielded L490A, allowing for greater flexibility in the hinging of the PBP.

Scanning Leu mutagenesis through the binding pocket aromatic residues showed the primacy of Y65, Y357, F12, and Y460 (**Figure 3b**). An aromatic side-chain screen across these four positions revealed a necessity of Tyr in the 1st shell positions Y65, Y357, and Y460 (**Figure 3c**). Substituting a noncanonical side chain, O-methyltyrosine, yielded a near-null biosensor at residue 65 but not at 12 (**Figure S4**). These data suggest that S-methadone's amine directly interacts with the 1st shell residues, as for nicotinic drugs, and the phenolic -OH is necessary for hydrogen bonding. The three accepted mutations represent a $94 \text{ \AA}^3$ reduction in van der Waals' volume, comparable to the $132 \text{ \AA}^3$ increase in ligand volume from varenicline to methadone, as though the accepted mutations allowed S-methadone better access to aromatic residues critical to binding both classes of drugs. Therefore, the PBP has an aromatic binding pocket for protonated amines, and other regions of the binding site can be tuned to accommodate the remainder of the ligand's steric bulk and functional groups.

iS-methadoneSnFR satisfied our sensitivity, selectivity, and biophysical criteria for a useful biosensor. Fluorescence dose-response relations showed an excellent dynamic range, $\Delta F_{\text{max}}/F_0$ of 15.3 ± 0.2 , and an EC_{50} , $3.2 \pm 0.2 \mu\text{M}$, near the relevant plasma concentrations for maintenance therapy⁸. Isothermal titration calorimetry (ITC) determined a K_d of $1.9 \pm 0.2 \mu\text{M}$, in good agreement with the fluorescence EC_{50} (**Figure 4c**). ITC also demonstrated a single binding site (stoichiometry = 0.92) with an entropically-driven conformational change. iS-methadoneSnFR had little or no response (S-slope $< 0.1 \mu\text{M}^{-1}$) to other neurotransmitters (**Figure 4a**) and other opioids (**Figure 4b**). The S-slope for S-methadone was $\sim 20\times$ that for R-methadone. When we added R-methadone to S-methadone, fluorescence was modestly elevated at lower [S-methadone], but all responses converged at the $\Delta F_{\text{max}}/F_0$ for S-methadone alone (**Figure S5**). 1-second stopped flow kinetics were obtained using racemic methadone (**Figure S4**) and determined an apparent k_{on} of $0.13 \mu\text{M}^{-1}\text{s}^{-1}$ (**Figure 4d**). The final 10 ms of the 1 second stopped-flow traces were fitted by a Hill equation with $\text{EC}_{50} \sim 8 \mu\text{M}$ (**Figure S6**) for the racemate, which was approximately double the EC_{50} for S-methadone alone (as expected if the binding strongly favors the S-enantiomer).

Therapeutic use of opioids would be improved by quantitative, real-time, minimally invasive or non-invasive measurements in sweat, saliva, and interstitial fluid.^{23,24} The selectivity and high aqueous solubility of iS-methadoneSnFR enable its use in such applications. We tested the biosensor in PBS:biofluid samples and found robust responses in the pharmacologically relevant concentration range (**Figure 5**). iS-methadoneSnFR, like all GFP-based biosensors, displays smaller responses at $\text{pH} \sim 7$ (**Figure S7**). Because biofluids, particularly sweat, have variable and/or acidic pH, 3x PBS was used to partially buffer a mixture with the biofluid. Still, the response at 1 μM and below in the biofluids provide at least $\sim 200\%$ dynamic range.

At the subcellular level, membrane-permeant weakly basic opioid drugs, but not impermeant derivatives or endogenous opioid peptides, enter the endoplasmic reticulum, and can act as pharmacological chaperones, altering the folding and trafficking of their receptors¹⁰. Opioid drugs also activate their receptors in endosomes and the Golgi apparatus¹¹. We targeted iS-methadoneSnFR to the plasma membrane, endoplasmic reticulum, and Golgi apparatus of HeLa using targeting sequences (**Figure 6a**). We applied pulses of S-methadone (0 to 250 nM in 50 nM steps) to measure the linear portion of the dose-response relation (S-slope) in widefield imaging (**Figure S8**). The results indicate that ample S-methadone is available in the ER for potential chaperoning. The Golgi showed the largest S-slope among the three compartments (1.7x that of PM), despite having the lowest

Figure 5: iS-methadoneSnFR dose-response relation in biofluids. 1:1 mixture of drug/biosensor in 3x PBS pH 7.4 with human sweat, human saliva, and 1:3 mixture with mouse serum (no pH adjustment of any biofluid).

pH (**Figure 6b**). After correcting the S-slope for pH dependence, we find an accumulation factor of 2.9x to 4.4x across the Golgi pH range of 6.3 to 6.8²⁵ (**Figure S8**). Accumulation of opioids such as methadone in acidic compartments²⁶ may lead to intensified G-protein coupled signaling. We also validated iS-methadoneSnFR for time-resolved measurements in primary hippocampal neurons, encouraging mechanistic studies in tissues and *in vivo* (**Figure S9**).

Along with other sensors of opioid signaling^{11,27}, this study establishes the first genetically encoded fluorescent protein biosensor for an opioid drug, enabling real-time quantification. Furthermore, the enantioselectivity encourages biosensor development to investigate “chiral switching” of other drugs where a single enantiomer substitutes a clinically used racemate²⁸. One enantiomer may serve previously unstudied indications. For example, S-methadone is now under clinical investigation as a rapidly acting antidepressant via non-opioid mechanism(s)²⁹. The directed evolution results demonstrate that the nicotinic PBP may be converted to detect

non-nicotinic small molecule amines by tuning residues around the aromatic 1st shell. Drug biosensors *in vivo* can monitor drug concentration near receptors during administration by the experimenter or the subject, a common manipulation for studying mechanisms of reward, analgesia, and drug abuse. To meet immediate needs for diagnostics, iS-methadoneSnFR can also provide *in situ* readouts in the laboratory or home.

Figure 6: (a) Spinning disc confocal imaging of HeLa cells transfected with iS-methadoneSnFR_PM, _ER, and _Golgi (470 nm excitation, 535 nm emission, 100x 1.4 NA objective). Scale bar = 10 microns. (b) S-slope plotted for each organelle response at 0-250 nM S-methadone. Points are average responses to a 1 min pulse of [S-methadone]. PM n = 11 cells; ER n = 10; Golgi n = 11.

Disclosure: AKM, HAL, LLL, and JSM have filed a patent that includes iS-methadoneSnFR.

Acknowledgements: The Caltech Center for Catalysis and Chemical Synthesis supported by the Beckman Institute supported the chiral resolution work. The CLOVER Center at Caltech and Gradinaru lab provided plasmids and advice for AAV production. Andres Collazo and Giada Spigolon manage the Biological Imaging Facility supported by the Beckman Institute and advised on confocal imaging. The Proteome Exploration Laboratory was supported by NIH OD010788, NIH OD020013, the Betty and Gordon Moore Foundation through grant GBMF775 and the Beckman Institute at Caltech. Wei Gao, You Yu, and Heather Lukas gathered human sweat. We thank Luke Lavis for contributive discussions. We thank Aiden Aceves and Stephen Mayo for advice on docking, Theodore Chin for assistance in cloning, and Purnima Deshpande for excellent lab management.

References:

- (1) Althoff, K. N.; Leifheit, K. M.; Park, J. N.; Chandran, A.; Sherman, S. G. Opioid-Related Overdose Mortality in the Era of Fentanyl: Monitoring a Shifting Epidemic by Person, Place, and Time. *Drug and Alcohol Dependence* **2020**, *216*, 108321. <https://doi.org/10.1016/j.drugalcdep.2020.108321>.
- (2) Dole, V. P. A Medical Treatment for Diacetylmorphine (Heroin) Addiction. **1965**, *198* (8), 646–650. <https://doi.org/10.1001/jama.1965.03090080008002>.
- (3) Dole, V. P. Methadone Maintenance Treatment for 25,000 Heroin Addicts. *JAMA* **1971**, *215* (7), 1131–1134. <https://doi.org/10.1001/jama.1971.03180200055012>.
- (4) *Handbook of Methadone Prescribing and Buprenorphine Therapy*, 1st ed.; Cruciani, R., Knotkova, H., Eds.; Springer: New York, New York.
- (5) Eap, C. B.; Buclin, T.; Baumann, P. Interindividual Variability of the Clinical Pharmacokinetics of Methadone: Implications for the Treatment of Opioid Dependence. *Clinical Pharmacokinetics* **2002**, *41* (14), 1153–1193. <https://doi.org/10.2165/00003088-200241140-00003>.
- (6) Li, Y.; Kantelip, J.-P.; Schieveen, P. G.; Davani, S. Interindividual Variability of Methadone Response: Impact of Genetic Polymorphism. *Mol Diag Ther* **2008**, *12* (2), 109–124. <https://doi.org/10.1007/BF03256276>.
- (7) Nilsson, M.-I.; Grönbladh, L.; Widerlöv, E.; Anggård, E. Pharmacokinetics of Methadone in Methadone Maintenance Treatment: Characterization of Therapeutic Failures. *Eur J Clin Pharmacol* **1983**, *25* (4), 497–501. <https://doi.org/10.1007/BF00542117>.
- (8) Foster, D. J. R.; Somogyi, A. A.; Dyer, K. R.; White, J. M.; Bochner, F. Steady-State Pharmacokinetics of (R)- and (S)-Methadone in Methadone Maintenance Patients: Pharmacokinetics of (R)- and (S)-Methadone. *British Journal of Clinical Pharmacology* **2000**, *50* (5), 427–440. <https://doi.org/10.1046/j.1365-2125.2000.00272.x>.
- (9) Lester, H. A.; Miwa, J. M.; Srinivasan, R. Psychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects. *Biological Psychiatry* **2012**, *72* (11), 907–915. <https://doi.org/10.1016/j.biopsych.2012.05.020>.
- (10) Petäjä-Repo, U. E.; Lackman, J. J. Targeting Opioid Receptors with Pharmacological Chaperones. *Pharmacological Research* **2014**, *83*, 52–62. <https://doi.org/10.1016/j.phrs.2013.12.001>.
- (11) Stoeber, M.; Jullié, D.; Lobingier, B. T.; Laeremans, T.; Steyaert, J.; Schiller, P. W.; Manglik, A.; von Zastrow, M. A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action. *Neuron* **2018**, *98* (5), 963–976.e5. <https://doi.org/10.1016/j.neuron.2018.04.021>.
- (12) Bick, M. J.; Greisen, P. J.; Morey, K. J.; Antunes, M. S.; La, D.; Sankaran, B.; Raymond, L.; Johnsson, K.; Medford, J. I.; Baker, D. Computational Design of Environmental Sensors for the Potent Opioid Fentanyl. *eLife* **2017**, *6*, e28909. <https://doi.org/10.7554/eLife.28909>.
- (13) Marvin, J. S.; Borghuis, B. G.; Tian, L.; Cichon, J.; Harnett, M. T.; Akerboom, J.; Gordus, A.; Renninger, S. L.; Chen, T.-W.; Bargmann, C. I.; Orger, M. B.; Schreiter, E. R.; Demb, J. B.; Gan, W.-B.; Hires, S. A.; Looger, L. L. An Optimized Fluorescent Probe for Visualizing Glutamate Neurotransmission. *Nat Methods* **2013**, *10* (2), 162–170. <https://doi.org/10.1038/nmeth.2333>.
- (14) Shivange, A. V.; Borden, P. M.; Muthusamy, A. K.; Nichols, A. L.; Bera, K.; Bao, H.; Bishara, I.; Jeon, J.; Mulcahy, M. J.; Cohen, B.; O’Riordan, S. L.; Kim, C.; Dougherty, D. A.; Chapman, E. R.; Marvin, J. S.; Looger, L. L.; Lester, H. A. Determining the Pharmacokinetics of Nicotinic Drugs in the Endoplasmic Reticulum Using Biosensors. *Journal of General Physiology* **2019**, *151* (6), 738–757. <https://doi.org/10.1085/jgp.201812201>.
- (15) Borden, P. M.; Zhang, P.; Shivange, A. V.; Marvin, J. S.; Cichon, J.; Dan, C.; Podgorski, K.; Figueiredo, A.; Novak, O.; Tanimoto, M.; Shigetomi, E.; Lobas, M. A.; Kim, H.; Zhu, P. K.; Zhang, Y.; Zheng, W. S.; Fan, C.; Wang, G.; Xiang, B.; Gan, L.; Zhang, G.-X.; Guo, K.; Lin, L.; Cai, Y.; Yee, A. G.; Aggarwal, A.; Ford, C. P.; Rees, D. C.; Dietrich, D.; Khakh, B. S.; Dittman, J. S.; Gan, W.-B.; Koyama, M.; Jayaraman, V.; Cheer, J. F.; Lester, H. A.; Zhu, J. J.; Looger, L. L. A Fast Genetically Encoded Fluorescent Sensor for Faithful in Vivo Acetylcholine Detection in Mice, Fish, Worms and Flies. *BioRxiv* **2020**. <https://doi.org/10.1101/2020.02.07.939504>.
- (16) Tian, L.; Hires, S. A.; Mao, T.; Huber, D.; Chiappe, M. E.; Chalasani, S. H.; Petreanu, L.; Akerboom, J.; McKinney, S. A.; Schreiter, E. R.; Bargmann, C. I.; Jayaraman, V.; Svoboda, K.; Looger, L. L. Imaging Neural Activity in Worms, Flies and Mice with Improved GCaMP Calcium Indicators. *Nat Methods* **2009**, *6* (12), 875–881. <https://doi.org/10.1038/nmeth.1398>.

- (17) Larsen, A. A.; Tullar, B. F.; Elpern, B.; Buck, J. S. The Resolution of Methadone and Related Compounds. *J. Am. Chem. Soc.* **1948**, *70* (12), 4194–4197. <https://doi.org/10.1021/ja01192a065>.
- (18) Bera, K.; Kamajaya, A.; Shivange, A. V.; Muthusamy, A. K.; Nichols, A. L.; Borden, P. M.; Grant, S.; Jeon, J.; Lin, E.; Bishara, I.; Chin, T. M.; Cohen, B. N.; Kim, C. H.; Unger, E. K.; Tian, L.; Marvin, J. S.; Looger, L. L.; Lester, H. A. Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. *Front. Cell. Neurosci.* **2019**, *13*, 499. <https://doi.org/10.3389/fncel.2019.00499>.
- (19) Zeisel, S. H.; Epstein, M. F.; Wurtman, R. J. Elevated Choline Concentration in Neonatal Plasma. *Life Sciences* **1980**, *26* (21), 1827–1831. [https://doi.org/10.1016/0024-3205\(80\)90585-8](https://doi.org/10.1016/0024-3205(80)90585-8).
- (20) Faessel, H. M.; Obach, R. S.; Rollema, H.; Ravva, P.; Williams, K. E.; Burstein, A. H. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation: *Clinical Pharmacokinetics* **2010**, *49* (12), 799–816. <https://doi.org/10.2165/11537850-000000000-00000>.
- (21) Russell, M. A.; Jarvis, M.; Iyer, R.; Feyerabend, C. Relation of Nicotine Yield of Cigarettes to Blood Nicotine Concentrations in Smokers. *BMJ* **1980**, *280* (6219), 972–976. <https://doi.org/10.1136/bmj.280.6219.972>.
- (22) Nichols, A. L.; Blumenfeld, Z.; Fan, C.; Luebbert, L.; Blom, A. E. M.; Cohen, B. N.; Marvin, J. S.; Borden, P. M.; Kim, C. H.; Muthusamy, A. K.; Shivange, A. V.; Knox, H. J.; Campello, H. R.; Wang, J. H.; Dougherty, D. A.; Looger, L. L.; Gallagher, T.; Rees, D. C.; Lester, H. A. *Fluorescence Activation Mechanism and Imaging of Drug Permeation with New Sensors for Smoking-Cessation Ligands*; preprint; Pharmacology and Toxicology, 2021. <https://doi.org/10.1101/2021.10.04.463082>.
- (23) Chung, M.; Fortunato, G.; Radacsi, N. Wearable Flexible Sweat Sensors for Healthcare Monitoring: A Review. *J. R. Soc. Interface.* **2019**, *16* (159), 20190217. <https://doi.org/10.1098/rsif.2019.0217>.
- (24) Soares Nunes, L. A.; Mussavira, S.; Sukumaran Bindhu, O. Clinical and Diagnostic Utility of Saliva as a Non-Invasive Diagnostic Fluid: A Systematic Review. *Biochem Med* **2015**, *25* (2), 177–192. <https://doi.org/10.11613/BM.2015.018>.
- (25) Rivinoja, A.; Pujol, F. M.; Hassinen, A.; Kellokumpu, S. Golgi PH, Its Regulation and Roles in Human Disease. *Annals of Medicine* **2012**, *44* (6), 542–554. <https://doi.org/10.3109/07853890.2011.579150>.
- (26) De Duve, C.; De Barsey, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. Lysosomotropic Agents. *Biochemical Pharmacology* **1974**, *23* (18), 2495–2531. [https://doi.org/10.1016/0006-2952\(74\)90174-9](https://doi.org/10.1016/0006-2952(74)90174-9).
- (27) Abraham, A. D.; Casello, S. M.; Schattauer, S. S.; Wong, B. A.; Mizuno, G. O.; Mahe, K.; Tian, L.; Land, B. B.; Chavkin, C. Release of Endogenous Dynorphin Opioids in the Prefrontal Cortex Disrupts Cognition. *Neuropsychopharmacol.* **2021**, *46* (13), 2330–2339. <https://doi.org/10.1038/s41386-021-01168-2>.
- (28) Long, A. S.; Zhang, A. D.; Meyer, C. E.; Egilman, A. C.; Ross, J. S.; Wallach, J. D. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review. *JAMA Netw Open* **2021**, *4* (5), e215731. <https://doi.org/10.1001/jamanetworkopen.2021.5731>.
- (29) Fogaça, M. V.; Fukumoto, K.; Franklin, T.; Liu, R.-J.; Duman, C. H.; Vitolo, O. V.; Duman, R. S. N-Methyl-D-Aspartate Receptor Antagonist d-Methadone Produces Rapid, MTORC1-Dependent Antidepressant Effects. *Neuropsychopharmacol.* **2019**, *44* (13), 2230–2238. <https://doi.org/10.1038/s41386-019-0501-x>.